Futura Medical plc (AIM: FUM), the innovative healthcare company focused on advanced transdermal technology today makes the following update on its block listings, pursuant to AIM Rule 29 and Schedule Six of the AIM Rules for Companies. All figures relate to options over Ordinary Shares.
The table below provides further detail. The figures include the block admission of 1,190,000 ordinary shares on 30 May 2018, as announced on 25 May 2018.
Number and class of securities not issued under the scheme(s) at beginning of period
USOS:
2,396,110
EMI:
2,671,390
Total:
5,067,500
Number and class of securities admitted to the scheme(s) in the period
USOS:
400,000
EMI:
790,000
Total:
1,190,000
Number of securities issued under the scheme(s) during the period Number of securities lapsed under the scheme(s) during the period
USOS:
(150,000)
EMI:
(160,000)
USOS:
(302,145)
EMI:
(457,855)
Balance of securities under the scheme(s) not yet issued at the end of the period
USOS:
2,343,965
EMI:
2,843,535
Total:
5,187,500
Number and class of securities originally admitted and the date of admission
USOS:
814,424 on 25 May 2011,
1,202,280 on 8 October 2013,
1,466,208 on 25 May 2017,
400,000 on 30 May 2018
USOS Total:
3,882,912
EMI:
1,520,576 on 25 May 2011,
1,467,720 on 8 October 2013,
1,893,792 on 25 May 2017,
790,000 on 30 May 2018
EMI Total:
5,672,088
Total:
9,555,000
Name of contact:
Angela Hildreth, Finance Director/COO
Telephone number of contact:
+44 (0) 1483 685 670
For media enquiries please contact:
Buchanan
Mark Court / Sophie Wills /
Stephanie Watson / Tilly Abraham
Tel: +44 (0) 20 7466 5000
Notes to Editors
Futura Medical plc
Futura Medical is a pharmaceutical group that develops innovative products for consumer healthcare. The Company is developing a portfolio of products and its strategy is to license their manufacture and distribution to major pharmaceutical and healthcare groups.
Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange.
www.futuramedical.com
Attachments
Original document
Permalink
Disclaimer
Futura Medical plc published this content on 30 May 2018 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 30 May 2018 09:57:03 UTC
Futura Medical plc is a United Kingdom-based pharmaceutical company. The Company is engaged in the development and sale of pharmaceutical and healthcare products. It is focused on developing a portfolio of products based on its transdermal DermaSys technology. The DermaSys is designed to deliver clinically proven medical treatments via the skin. DermaSys platform with penetration and permeation enhancer components tailored for each product to suit the specific therapeutic indication and desired speed of onset and duration of action. Such targeted delivery offers an optimized profile in terms of dose, onset time and duration of effect. The Company's products include MED3000 and TPR100. The Company's lead product, MED3000, is a topical gel formulation treatment for erectile dysfunction (ED) through an evaporative mode of action. The Company has conducted a Phase III study using MED3000 in ED. The Company is also developing CBD100, which is a topical cannabidiol formulation.
FUTURA MEDICAL PLC 
